Benzydamine/ Cetylpyridinium

Registered South African indications: 

• Painful conditions of the mouth and throat

Combination products may have additional pharmacological effects not accounted for by the action of the individual ingredients

Benzydamine
Contraindications

• Hypersensitivity to the active ingredient or any of the excipients in this combination product

Cautions

• Breastfeeding
• Avoid contact with eyes

Cetylpyridinium
Contraindications

• Hypersensitivity to the active ingredient or any of the excipients in this combination product

Cautions

• Pregnancy
• Breastfeeding
• Prolonged use

Forms avail. in SA and covered in this monograph: loz, gel

Symptomatic relief of painful inflammatory conditions of the mouth

Benzydamine/ Cetylpyridinium
10/1 (mg)

• Oral (gel): Apply small quantity to the affected area, 2-3hrly; Max applications: 12/24hrs

Do not eat or drink for 15min after application

Symptomatic relief of minor infections and painful conditions of the mouth or throat

Benzydamine/ Cetylpyridinium
3/1.33 (mg) 

• Oral (loz): 1 loz, 1-2hrly; Max: 12 loz/day; Max duration: 7 days

Suck slowly, do not chew

Paed. forms avail. in SA and covered in this monograph: gel, loz

Symptomatic relief of painful inflammatory conditions of the mouth

Benzydamine/ Cetylpyridinium
10/1 (mg) 

• Younger than 6 years: Not established for use
• Older than 6 years: See adult dosage

Symptomatic relief of minor infections and painful conditions of the mouth or throat

Benzydamine/ Cetylpyridinium
3/1.33 (mg)

• Younger than 6 years: Not established for use
• Older than 6 years: See adult dosage

Recommendations for this combination product as per highest risk category when comparing individual active ingredients

Pregnancy

• FDA Pregnancy Category Not Rated (NR) (Benzydamine, Cetylpyridinium) 

Breastfeeding

• Caution; not recommended (Benzydamine)

Renal Impairment

• No dose adjustment recommended (Benzydamine, Cetylpyridinium)

Hepatic Impairment

• No dose adjustment recommended (Benzydamine, Cetylpyridinium)

Elderly

• No dose adjustment recommended (Benzydamine, Cetylpyridinium)

Porphyria Information

• Not porphyrinogenic (NP)

Drugs in Sport

• Permitted - No warning

Combination products may have additional pharmacological effects not accounted for by the action of the individual ingredients

Benzydamine
Respiratory  Disorders

• Laryngospasm
• Bronchospasm

Gastrointestinal Disorders

• Oral numbness 
• A stinging feeling in the mouth
• Nausea and vomiting

Skin and Subcutaneous Tissue Disorders

• Hypersensitivity reactions
• Angioedema

Immune, Blood and Lymphatic System Disorders

• Anaphylaxis 

Cetylpyridinium
Gastrointestinal Disorders

• Nausea and vomiting
• Tongue discolouration
• Mouth irritation

Skin and Subcutaneous Tissue Disorders

• Irritant
• Burning

Immune, Blood and Lymphatic System Disorders

• Hypersensitivity reaction

Combination products may have additional pharmacological effects not accounted for by the action of the individual ingredients

Benzydamine
Cetylpyridinium

• No information available

None routine

Benzydamine
An indazole non-steroidal anti-inflammatory drug (NSAID) with analgesic, antipyretic, and anti-oedema properties. Unlike other NSAIDs, benzydamine hydrochloride does not inhibit cyclooxygenases but stabilizes membranes, resulting in local anaesthesia and inhibits the production of pro-inflammatory cytokines.

Cetylpyridinium chloride
Cetylpyridinium chloride is a cationic antiseptic with activity against both gram positive and gram negative organisms.

COMBINATION PREPARATIONS

Benzydamine/ Cetylpyridinium

Lozenges 3mg/1.33mg 

• Andolex C Raspberry (iNova) originator (Discontinued: 12/07/2021)
• Andolex C Eucaluptus Menthol (iNova) originator
• Andolex C Orange (iNova) originator (Discontinued: 12/07/2021)
• Andolex C Honey and Lemon (iNova) originator (Discontinued: 12/07/2021)

Benzydamine/ Cetylpyridinium

Gel (per g) 10mg/1mg 

• Andolex C Oral Gel (iNova) originator